Status:
COMPLETED
PREDICTIVE IMMUNOLOGICAL STUDY OF RECURRENT ABORTIONS AND IMPLANTATION FAILURE
Lead Sponsor:
IVI Madrid
Conditions:
Maternal-Fetal KIR-HLA-C Compatibility
Eligibility:
FEMALE
18-45 years
Brief Summary
The involvement of the immune system in the process of implantation and its modulation as a therapeutic line in these alterations, failure of implantation and repetition abortion are controversial and...
Detailed Description
A prospective pilot study is proposed in patients with recurrent implantation failure and recurrent abortions undergoing assisted reproductive techniques. The main objective of this study is to deter...
Eligibility Criteria
Inclusion
- Inclusion Criteria in recurrent implantation failure:
- Body mass index between 19 and 27 kg/m2
- Patients with 3 or more IVF failures following transfer of good quality embryos or with 2 or more failures following embryo transfer in egg donation cycles.
- At least one embryo transfer is required to have been made in a blastocyst state (embryo on day 5) and with the current partner/donor.
- Study of normal karitype..
- Normal thrombophilia study.
- Vaginal exudate (Chlamydia, ureaplasma) normal
- Normal immune study.
- No hormone treatment in the two months prior to inclusion in the study.
- Inclusión criteria in recurrent abortion:
- Body mass index between 19 and 27 kg/m2
- Patients with 3 or more recurrent abortions, natural gestations or after transfer of good quality embryos (own or ovodonation)
- Study of normal karitype.
- Normal thrombophilia study.
- Vaginal exudate (Chlamydia, ureaplasma) normal
- Normal immune study.
- No hormone treatment in the two months prior to inclusion in the study.
- Exclusion Criteria:
- Pregnant or lactating women.
- They cannot offer cooperation.
- Participation in a study or clinical trial during the 3 months prior to inclusion.
- Patients with fibromes.
- Patients with PCOS.
- Patients with some genetic alteration (altered karitype, cystic fibrosis, multiple sclerosis, rheumatoid arthritis...)
- Patients chronic infectious disease.
- Patients in maintenance treatment with immunosuppressants.
- Patients who have received systemic corticosteroids in the last 4 weeks.
- Patients diagnosed with chronic lymphoproliferative disease.
Exclusion
Key Trial Info
Start Date :
January 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2017
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04052438
Start Date
January 1 2015
End Date
January 1 2017
Last Update
August 21 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.